scandiononcology logo

Scandion Oncology A/S

Scandion Oncology A/S is developing therapies to re-sensitize cancer cells to chemotherapy within metastatic colon and breast cancer.

KEY DETAILS

Websitehttps://scandiononcology.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
COBIS Ole Maaløesvej 3 DK 2200, N
Copenhagen
Denmark
Email
Contact Number
+45 26144708

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/scandion-oncology” connections=”true” suffix=””]

In Dec 2017, Scandion Oncology raised DKK 2 Mn in a private placement from various investors. The company plans to utilise the proceeds to develop its lead compound, SCO-101, for the treatment of chemotherapy resistant cancer.